Premium
Orphan medicines: the high cost of hope
Author(s) -
Houlton Sarah
Publication year - 2018
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1640
Subject(s) - orphan drug , medicine , nice , incentive , investment (military) , alternative medicine , bioinformatics , law , economics , pathology , market economy , computer science , political science , biology , programming language , politics
Orphan drugs can transform the lives of patients with rare diseases, but they often come at an extremely high cost. Sarah Houlton discusses the incentives that are encouraging pharma investment in orphan drug research and the steps that NICE and the NHS are taking to budget for these treatments as they come to market.